Skip to main content
Clinical Trials/ISRCTN18043449
ISRCTN18043449
Completed
Phase 4

A prospective, single-centre, open-label, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and the impact on the MUSculoskeletal system of skin-directed therapy with usTEKinumab

niversity of Leeds (UK)0 sites73 target enrollmentSeptember 19, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Psoriatic disease (psoriasis and psoriatic arthritis)
Sponsor
niversity of Leeds (UK)
Enrollment
73
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Registry
who.int
Start Date
September 19, 2012
End Date
October 1, 2014
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Leeds (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Male and female patients aged 18\-80 years
  • 2\. Diagnosis of plaque psoriasis (dermatologist confirmed)
  • 3\. Duration of psoriasis greater than twelve months
  • 4\. Moderate or severe disease \[Psoriasis Area and Severity Index (PASI score \>10\)]
  • 5\. No prior treatment with systemic or biologic agents
  • 6\. No current or prior symptoms of psoriatic arthritis (or arthralgia/ articular symptoms)
  • 7\. Evidence on screening ultrasound of subclinical enthesitis (GUESS score \>12\)
  • 8\. All male and female subjects biologically capable of having children must agree to use at least one reliable method of contraception for the duration of the study and for 24 weeks after the end of the study. Acceptable methods of contraception are surgical sterilization, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives

Exclusion Criteria

  • 1\. Patients aged 17 or under, or 81 and over
  • 2\. Psoriasis of mild to moderate psoriasis (PASI\<10\)
  • 3\. Previous treatment with any systemic or biologic agents (for psoriasis or any other indication)
  • 4\. Patients unable or not willing to attend all imaging, serological and clinical assessments
  • 5\. Any contraindication to MRI (e.g. pacemaker, aneurysm coil)
  • 6\. Patients not willing to use adequate contraception
  • 7\. Pregnancy or breast feeding
  • 8\. Any contraindication to systemic or biologic therapy:
  • 8\.1\. Active infection, including open leg ulcers, HIV, hepatitis B or C carriers
  • 8\.2\. Active or latent tuberculosis

Outcomes

Primary Outcomes

Not specified

Similar Trials